The Waiting Game
In the next year, the expected approval of small molecules targeting hepatitis C will usher in a new era in treatment
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
May 3, 2010 Cover
Volume 88, Issue 18
In the next year, the expected approval of small molecules targeting hepatitis C will usher in a new era in treatment
Credit:
In the next year, the expected approval of small molecules targeting hepatitis C will usher in a new era in treatment
Long overshadowed by amyloid-β, tau protein is gaining ground as a therapeutic target in alzheimer's disease
Offshore drilling is being used as a political chip in an effort to secure a climate deal
Chemical innovations make tasty battlefield meals, ready-to-eat
Researchers gaining exposure to industrial science are encouraged to publish
When in Cambridge, major drug companies play by Cambridge rules in a quest for breakthroughs
An asteroid between Mars and Jupiter is unexpectedly covered in water ice and organic compounds